Eliquis has continued to deliver a strong performance with revenues up 25% operationally to $1.6 billion in the first quarter. In the U.S., Eliquis sales growth was driven mainly by strong volume growth. VYNDAQEL and VYNDAMAX generated revenues of $453 million, representing operational growth o...
- REVENUES NINE MONTHS 2023 and 2022 - (UNAUDITED) (MILLIONS) TOTAL REVENUES GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(b) Primary Care Comirnaty direct sales and alliance revenues(c) Eliquis alliance revenues and direct sales Prevnar family(d) Paxlovid Nurtec ODT/Vydura Abrysvo Premarin ...
ELIQUIS (apixaban) ELLENCE® (epirubicin hydrochloride) ELREXFIO™ (elranatamab) EMCYT® (estramustine phosphate sodium) ENALAPRILAT (enalaprilat) EPINEPHRINE (epinephrine) ERAXIS™ (anidulafungin) Ertapenem (Ertapenem) ERYTHROCIN™ LACTOBIONATE ...